What are the contraindications of ibrutinib/Eco and what should you pay attention to when using it?

Ibrutinib/Ibrutinib (Ibrutinib), as a targeted therapy, has shown significant efficacy in the treatment of a variety of B cell-related malignant tumors (non-Hodgkin lymphoma). However, despite its outstanding efficacy, the use of ibrutinib still requires strict compliance with contraindications and precautions to ensure patient safety and therapeutic efficacy.

First, one of the contraindications to ibrutinib is patients who are allergic to the drug or any of its components. Allergic reactions include symptoms such as rash, shortness of breath, facial swelling, etc. Once similar allergic reactions occur, you should stop taking the drug immediately and seek medical help. In addition, patients with hepatic impairment need to be particularly careful when using ibrutinib, because the drug is metabolized by the liver, and patients with poor liver function may cause the drug concentration to be too high in the body, thereby increasing the risk of adverse reactions.

Secondly, ibrutinib is not suitable for use in patients with severe bleeding risks. Ibrutinib may cause bleeding tendencies, especially in patients with concomitant anticoagulant use, thrombocytopenia, or coagulopathy. For patients who are receiving anticoagulant therapy (such as warfarin, low molecular weight heparin, etc.), platelet and coagulation functions need to be strictly monitored when using ibrutinib to avoid the occurrence of bleeding complications.

In addition, ibrutinib should be used with caution in patients with a history of severe heart disease. Clinical studies have shown that ibrutinib may cause irregular heartbeats, especially in patients with heart disease, which may lead to heart problems such as atrial fibrillation. Therefore, patients with heart disease, especially those with a history of atrial fibrillation, coronary heart disease, etc., need to regularly monitor their heart health when using ibrutinib and seek medical treatment promptly if they have symptoms such as irregular heartbeat.

When using ibrutinib, patients should also regularly monitor hematological indicators, including platelet count, liver function, renal function, etc., in order to detect possible abnormalities in a timely manner. Especially patients with abnormal liver function or renal insufficiency need to be particularly careful when using this drug to avoid drug accumulation and serious adverse reactions.

Reference materials:https://www.imbruvica.com/